- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Steven Yates Shares His Institutions's Policies on Nonmedical Switching and New Biosimilar Starts
Steven Yates, MD, discusses Intermountain Healthcare's policies surrounding switching patients from reference products to biosimilars.
The Center for Biosimilars® interviewed Steven Yates, MD, a medical oncologist and medical director at Intermountain Healthcare in Las Vegas, Nevada. Three years ago, Intermountain hired him to lead its biosimilar adoption effort.
Dr Yates describes Intermountain’s experience with switching patients to biosimilars vs initiating biosimilar treatment only for biologics-naïve patients. Early on, Intermountain did not switch patients from reference products until their course of therapy was complete. Intermountain is now 100% biosimilar focused, Yates says. Strong patient support is employed to build acceptance for biosimilars, and patients are asked for consent prior to a biosimilar switch. Yates says the institution has experienced little pushback, and the resistance that has occurred has been mostly over reimbursement issues, where patient assistance programs have preferred use of reference products.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
